Drug
HN2301 injection
HN2301 injection is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/1)
Active Trials
1(33%)
Terminated
1(33%)
Phase Distribution
Ph not_applicable
1
33%
Ph phase_1
2
67%
Phase Distribution
2
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Terminated(1)
Detailed Status
Not yet recruiting1
Terminated1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
0.0%
Most Advanced
Phase 1
Trials by Phase
Phase 12 (66.7%)
N/A1 (33.3%)
Trials by Status
not_yet_recruiting133%
terminated133%
recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
not_yet_recruitingphase_1
Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)
NCT07556120
recruitingphase_1
Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）
NCT06801119
terminatednot_applicable
Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG)
NCT06965309
Clinical Trials (3)
Showing 3 of 3 trials
NCT07556120Phase 1
Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)
NCT06801119Phase 1
Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）
NCT06965309Not Applicable
Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG)
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3